Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD-Reference-Cited by-同舟云学术

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

Published:2022-04-15 Issue:7 Volume:28 Page:981-991
ISSN:1755-5930
Container-title:CNS Neuroscience & Therapeutics
language:en
Short-container-title:CNS Neurosci Ther

Author:

Shi Mingchao¹²,Chu Fengna¹²^ORCID,Jin Tao¹,Zhu Jie¹²

Affiliation:

1. Neuroscience Center Department of Neurology The First Hospital of Jilin University Changchun China

2. Department of Neurobiology, Care Sciences & Society Division of Neurogeriatrcs Karolinska Institutet Karolinska University Hospital Solna Stockholm Sweden

Publisher

Wiley

Subject

Pharmacology (medical),Physiology (medical),Psychiatry and Mental health,Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cns.13836

Reference107 articles.

1. Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System

2. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

3. Neuromyelitis Spectrum Disorders

4. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide

5. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heterogenous relapse and efficacy endpoint definitions for neuromyelitis optica spectrum disorder studies: A systematic review;Multiple Sclerosis and Related Disorders;2024-11

2. Overview of emerging therapies for demyelinating diseases;World Journal of Clinical Cases;2024-10-26

3. Short-Term Efficacy Analysis of Glucocorticoid Combined with Intravenous Immunoglobulin (IVIG) in the Treatment of Acute Exacerbation of Neuromyelitis Optica;2024-08-19

4. Therapeutic Management of Transverse Myelitis Secondary to Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease;American Journal of Therapeutics;2024-07

5. Course of myelin oligodendrocyte glycoprotein-associated disease (MOGAD) – a cohort of patients;Česká a slovenská neurologie a neurochirurgie;2024-04-30